Review on Regulatory Affairs in the Era of Artificial Intelligence: Roles, Needs, and Evolving Responsibilities

Regulatory affairs are the backbone of the pharmaceutical industry, ensuring that drugs and medical products meet strict safety, efficacy, and quality standards. Over time, this field has evolved in response to scientific advancements, global collaboration, and the growing focus on patient-centric care. Historically, major public health crises led to the creation of key regulatory agencies like the FDA and EMA, which established standardized processes to protect public health. Today, regulatory professionals navigate complex challenges, from stringent clinical trial requirements to evolving digital health regulations and increasing transparency demands. Agencies are refining approval pathways, such as expedited reviews for breakthrough therapies, to accelerate drug development while maintaining safety. Emerging technologies like AI, big data, and real-world evidence are also transforming regulatory decision-making. Looking ahead, the future of regulatory affairs will be shaped by automation, personalized medicine, and adaptive regulatory frameworks. Innovations in precision medicine, gene therapy, and AI-driven analytics will drive efficiency and flexibility. Global regulatory harmonization efforts will further streamline processes, ensuring faster access to groundbreaking treatments. As the landscape continues to evolve, pharmaceutical companies and regulators must stay ahead of emerging trends to balance compliance with innovation in drug development.